Ozempic and Women's Health: Beyond Weight Loss

What these medications actually do (beyond weight loss)

GLP-1 is a hormone your gut naturally releases when you eat. It tells your pancreas to release insulin, slows how fast your stomach empties, and most importantly, tells your brain you're full. The medications are synthetic versions. The critical point: GLP-1 receptors aren't just in your gut. They're in your heart, your brain, your reproductive organs, your bones. This receptor distribution throughout your body is why these drugs do so much more than suppress appetite. While most media coverage focuses on weight loss, research shows the systemic effects matter at least as much.

Semaglutide (Ozempic for diabetes, Wegovy for weight loss) and tirzepatide (Mounjaro) are the two everyone knows about. They're injected weekly. The weight loss is real: 14.9% body weight reduction on semaglutide in trials. If you weigh 200 pounds, you'd lose roughly 28 pounds on average over the trial period. Tirzepatide shows up to 22% reduction. At the same starting weight, you could lose up to 44 pounds. But that's just the headline. What matters for your specific health depends on the other effects happening simultaneously.

Fertility: your cycle comes back (and you might not notice)

Here's something most people don't realize: GLP-1 medications can restore ovulation in women who stopped ovulating. This happens especially if you have PCOS, obesity-driven cycle loss, or cycle loss from being underfed. As you lose weight and your insulin sensitivity improves, your androgen levels drop, and your brain essentially says "okay, it's safe to ovulate again." Women who'd been infertile because of PCOS suddenly become fertile. Without realizing it. That's clinically important because these medications are contraindicated in pregnancy. Animal studies show they increase miscarriage risk and birth defects. You need contraception that's foolproof, and you need to know your cycle came back (because a lot of women assume broken cycles stay broken).

The other catch: oral contraceptive pills rely on stomach acid to absorb. GLP-1 slows stomach emptying. So pills may not absorb properly. Non-pill methods (IUD, implant, injection, patch) aren't affected. This is worth discussing with your prescriber, but it's not widely known.

PCOS specifically (where these drugs actually shine)

PCOS affects 1 in 10 women of reproductive age. It's characterized by insulin resistance, too much testosterone, and broken cycles. GLP-1 medications address all three. They improve insulin sensitivity, which lowers testosterone, which fixes your cycle. Small trials and observational data show semaglutide reduces testosterone levels, restores periods, and reduces facial hair in women with PCOS. The effects are mostly from weight loss and better insulin sensitivity, not from the drug directly, but the combination works.

A 2023 randomized trial found semaglutide outperformed metformin (the standard PCOS treatment) at improving hormones and cycle regularity over 24 weeks. This is the area where GLP-1 medications have the strongest specific evidence in women. They're likely to become standard PCOS treatment alongside or instead of metformin, though guidelines are still catching up.

Bone loss (the overlooked side effect)

Rapid weight loss from any source (surgery, dieting, drugs) causes bone loss. GLP-1 drugs are no exception. A 2024 analysis found semaglutide treatment caused measurable reductions in bone mineral density at the spine and hip, with bigger losses in people who lost more weight. This matters especially for women. You already have lower peak bone mass than men. During perimenopause, bone loss accelerates. Combine rapid weight loss from GLP-1 with declining estrogen, and your bones take a real hit.

If you're over 45 and considering these medications, calcium and vitamin D become non-negotiable (1000-1200mg calcium, 800-2000 IU vitamin D daily). Weight-bearing and resistance exercise isn't optional: it's bone-protective. A DEXA scan to measure baseline bone density makes sense if you have other risk factors. This is where most doctors don't mention the full picture. The weight-loss benefits are real, but you can't ignore what's happening to your skeleton.

Muscle loss (why strength training becomes essential)

GLP-1 medications work by making you eat less. When you eat significantly less, your body loses weight from both fat and muscle. Without resistance training, up to 40% of your weight loss is muscle, not fat. Which means your metabolism will stay sluggish and muscle-building will take far longer after you stop the medication. That's not just cosmetic: lost muscle tanks your metabolism, reduces your strength, and accelerates age-related muscle loss. For women already fighting lower muscle mass than men and facing sarcopenia (age-related muscle wasting) from the mid-40s onward, this is a real problem with long-term consequences.

If you're on GLP-1, resistance training stops being optional. It's like taking the medication. Protein intake matters too: aim for 1.2-1.6g per kilogram of body weight daily from leucine-rich sources (eggs, yogurt, fish, chicken, legumes). Creatine supplementation has solid evidence for protecting muscle during caloric restriction and is worth considering. Imperfect clarity moment: most prescribers don't emphasize how much muscle you'll lose without deliberate exercise. They should.

Brain and mood (surprisingly positive)

GLP-1 receptors are all over your brain in areas that control reward, mood, and motivation. That's why these drugs might do something unexpected: improve mental health. Observational studies show people on semaglutide report fewer depression symptoms, reduced alcohol cravings, and reduced substance-seeking behavior. It's not huge, but it's consistent enough that the FDA actually investigated whether these drugs might increase suicidality. The 2024 review found the opposite: no suicide signal, and possibly protective effects for mood in some people. The surprise insight: appetite suppression and mood effects happen through the same brain pathways. As you suppress hunger signals, you may also dampen reward-seeking and cravings in general.

There's also early research on GLP-1 drugs for Alzheimer's disease, based on evidence that GLP-1 receptors in the brain reduce inflammation and clear amyloid (the toxic protein in Alzheimer's). Phase 3 trials are running. Don't use GLP-1 for dementia prevention yet, but it's part of the bigger picture of how these drugs affect your brain beyond appetite.

Heart protection (beyond weight loss)

The SELECT trial (2023) is the big one. It followed 17,600+ people with obesity and existing heart disease for three years. People on semaglutide had 20% fewer heart attacks, strokes, and cardiovascular deaths than placebo. Which means the medication reduces your absolute risk of a major cardiovascular event by a meaningful margin—a benefit that's separate from the weight loss itself. The surprise: some of this protection happened independent of weight loss. The GLP-1 receptor itself appears to protect your cardiovascular system through inflammation reduction and blood vessel improvements. That matters because it means these drugs aren't just weight-loss vehicles: they have direct heart benefits.

For women, this is relevant during the midlife transition when cardiovascular risk spikes after estrogen declines. If you have existing heart disease or heart-disease risk factors, this is a genuine additional benefit beyond weight reduction. It doesn't mean healthy women should take GLP-1 for heart protection, but it frames these drugs as having systemic benefits beyond the number on the scale.

What Women Starting GLP-1 Medications Should Know